Skip to main content

Table 7 Correlations of methylation levels of the promoter region of hTERT gene with baseline characteristics of patients in the recurrence and non-recurrence groups

From: The correlations between DNA methylation and polymorphisms in the promoter region of the human telomerase reverse transcriptase (hTERT) gene with postoperative recurrence in patients with thyroid carcinoma (TC)

Characteristic

Non-recurrence group

Recurrence group

 

Hypomethylation (%)

Hypermethylation (%)

P

Hypomethylation (%) (n = 22)

Hypomethylation (%) (n = 53)

P

Tumor size

 <20 mm

112 (70.0)

45 (58.4)

0.078

12 (54.5)

19 (35.8)

 

 ≥20 mm

48 (30.0)

32 (41.6)

 

10 (45.5)

34 (64.2)

0.134

Multicentricity

 Yes

102 (63.8)

41 (53.2)

0.122

9 (40.9)

27 (50.9)

 

 No

58 (36.3)

36 (46.8)

 

13 (59.1)

26 (49.1)

0.428

Extrathyroidal invasion

 Yes

57 (35.6)

31 (40.3)

0.489

8 (36.4)

25 (47.2)

0.391

 No

103 (64.4)

46 (59.7)

 

14 (63.6)

28 (52.8)

 

Lymph node metastasis

 Yes

29 (18.1)

15 (19.5)

0.802

7 (31.8)

41 (77.4)

<0.001

 No

131 (81.9)

62 (80.5)

 

15 (68.2)

12 (22.6)

 

Pathological type

 Papillary thyroid carcinoma

147 (91.9)

73 (94.8)

0.707

12 (54.5)

25 (47.2)

 

 Follicular thyroid carcinoma

7 (4.4)

3 (3.9)

 

2 (9.1)

5 (9.4)

 

 Medullary thyroid carcinoma

4 (2.5)

1 (1.3)

 

2 (9.1)

8 (15.1)

 

 Undifferentiated carcinoma

2 (1.3)

0 (0.0)

 

6 (27.3)

15 (28.3)

0.897

Tumor stage

 I + II

135 (84.4)

64 (83.1)

0.805

14 (63.6)

16 (30.2)

 

 III + IV

25 (15.6)

13 (16.9)

 

8 (36.4)

37 (69.8)

0.007

  1. hTERT human telomerase reverse transcriptase